Why did Komen for the Cure give Nancy Brinker a 64 percent raise?
Last year may have been a very bad year for the Susan G. Komen Foundation, but it still was a very good year for its CEO, Nancy Brinker. Extravagantly good.
In 2012, the breast cancer organization ignited a firestorm by announcing it was pulling its funding for breast cancer screenings and services for Planned Parenthood -- and then had to hastily and ineptly apologize, then backpedal. It watched as its conspicuously conservative vice president for public policy Karen Handel resigned in the wake of the scandal. It saw registrations for its events decline in Maryland, in Texas, and all over the damn place. It squirmed at increasing questions over why an organization that features the words "the cure" so heavily in its promotion, that boasts how its "research investment has changed the breast cancer landscape," devotes a miniscule and declining portion of its dollars to actually finding one.